医薬品製剤開発・製造の世界市場予測（～2024年）...市場調査レポートについてご紹介

1 Introduction (Page No. – 18)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. – 21)
2.1 Research Approach
2.1.1 Secondary Research
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Research
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Breakdown of Primaries
2.1.2.3 Key Industry Insights
2.2 Market Size Estimation
2.3 Data Triangulation Approach
2.4 Market Players Ranking Analysis
2.5 Assumptions for the Study
3 Executive Summary (Page No. – 28)
4 Premium Insights (Page No. – 32)
4.1 Pharmaceutical Contract Development and Manufacturing: Market Overview
4.2 Pharmaceutical Contract Development and Manufacturing Market: Geographic Growth Opportunities
4.3 Regional Mix: Pharmaceutical Contract Development and Manufacturing Market (2019–2024)
4.4 Pharmaceutical Contract Development and Manufacturing Market: Developed vs. Developing Markets, 2019 vs. 2024
5 Market Overview (Page No. – 36)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing Demand for Generics
5.2.1.2 Increasing Investments in Pharmaceutical R&D
5.2.1.3 Investments in Advanced Manufacturing Technologies By Cdmos
5.2.2 Opportunities
5.2.2.1 Increasing Demand for Biological therapies
5.2.2.2 Growing Focus on Specialty Medicines
5.2.2.3 Growth in the Nuclear Medicine Sector
5.2.2.4 Growing Demand for Cell and Gene therapies
5.2.3 Challenges
5.2.3.1 Introduction of Serialization
5.2.3.2 Changing Trade Policies Between Countries
5.2.4 Trends
5.2.4.1 Increasing Cdmo Manufacturing Footprint in Asian Countries
5.2.4.2 Cdmo Industry Consolidation
5.2.4.3 Increasing Outsourcing of Clinical Trials to Emerging Markets
6 Pharmaceutical Contract Development and Manufacturing Market, By Service (Page No. – 46)
6.1 Introduction
6.2 Pharmaceutical Manufacturing Services
6.2.1 Pharmaceutical Api Manufacturing Services
6.2.1.1 Need to Cut Costs and Ensure Focus on Core Areas Leads Companies to Outsource Api Manufacturing
6.2.2 Pharmaceutical FDF Manufacturing Services
6.2.2.1 Parenteral/Injectable Manufacturing Services
6.2.2.1.1 Need for High Levels of Expertise and Growing Drug Development Activity are Driving the Demand for Contract Manufacturing
6.2.2.2 Tablet Manufacturing Services
6.2.2.2.1 Shifting Manufacturing Requirements and Need to Streamline Production Processes Is Driving Market Growth
6.2.2.3 Capsule Manufacturing Services
6.2.2.3.1 Growth in Demand for Capsule Formulations has Ensured Growth Opportunities for Service Providers
6.2.2.4 Oral Liquid Manufacturing Services
6.2.2.4.1 Complexities Involved in Oral Liquid Manufacturing Have Prompted Companies to Look to Outsourcing
6.2.2.5 Other Formulations
6.3 Drug Development Services
6.3.1 Drug Substance Complexity and High Costs Have Supported the Outsourcing of Drug Development
6.4 Biologics Manufacturing Services
6.4.1 Biologics Api Manufacturing Services
6.4.1.1 The Market for Biologics Api Manufacturing Is Still in the Emergent Phase
6.4.2 Biologics FDF Manufacturing Services
6.4.2.1 Increasing R&D Costs and Process Complexity Have Prompted the Shift Toward Contract Manufacturing
7 Pharmaceutical Contract Development and Manufacturing Market, By End User (Page No. – 68)
7.1 Introduction
7.2 Big Pharma
7.2.1 Emergence of New Medicines and therapy Forms to Contribute to the Growth of This Market
7.3 Small & Mid-Size Pharma
7.3.1 Growing Development of Biologic Drugs and High Pricing Pressure to Boost Market Growth
7.4 Generic Pharmaceutical Companies
7.4.1 Growing Demand for Generics to Support Market Growth
7.5 Other End Users
8 Pharmaceutical Contract Development and Manufacturing Market, By Region (Page No. – 76)
8.1 Introduction
8.2 Europe
8.2.1 Italy
8.2.1.1 Increasing Focus on Clinical Research and the Growing Popularity of Branded Drugs are Driving the Demand for Contract Development and Manufacturing
8.2.2 Germany
8.2.2.1 High Healthcare Expenditure and Increased Pharmaceutical Production to Support Market Growth
8.2.3 France
8.2.3.1 Presence of Leading Pharmaceutical Companies to Support Market Growth in France
8.2.4 UK
8.2.4.1 Growth in the Generics Market and the Rising Cost of Manufacturing Parenteral Formulations are Driving Market Growth
8.2.5 Switzerland
8.2.5.1 Large Volume of Pharmaceutical Production and Growing Scope for Generics Is Expected to Growth Opportunities
8.2.6 Spain
8.2.6.1 Increase in Biologics Production to Support Market Growth
8.2.7 Rest of Europe
8.3 North America
8.3.1 US
8.3.1.1 The US Dominates the North American Pharmaceutical Contract Development and Manufacturing Market
8.3.2 Canada
8.3.2.1 Growth of the Emerging Markets and Slowdown in New Product Approvals Will Hamper Market Growth
8.4 Asia Pacific
8.4.1 India
8.4.1.1 Low Manufacturing Costs and A Skilled Workforce are Factors Attracting Outsourcing and Investment to India
8.4.2 China
8.4.2.1 Favorable Government Regulations are Fueling Market Growth in China
8.4.3 Japan
8.4.3.1 Growing Generics Demand and Push From the Government Will Drive the Demand for Contract Manufacturing of Drugs
8.4.4 Rest of Asia Pacific
8.5 Latin America
8.5.1 Favorable Cost Structure and Government Investments to Drive Pharmaceutical Production in Latam
8.6 Middle East & Africa
8.6.1 Government Support to Boost Local Production Is Expected to Offer Growth Opportunities for the Contract Manufacturers in the Region
9 Competitive Landscape (Page No. – 132)
9.1 Overview
9.2 Market Ranking
9.2.1 Pharmaceutical Contract Development and Manufacturing Market, By Key Players, 2018
9.3 Competitive Leadership Mapping
9.3.1 Visionary Leaders
9.3.2 Innovators
9.3.3 Dynamic Differentiators
9.3.4 Emerging Companies
9.4 Competitive Situation and Trends
9.4.1 Product Launches
9.4.2 Expansions
9.4.3 Acquisitions
9.4.4 Agreements, Partnerships, and Collaborations
10 Company Profiles (Page No. – 142)
(Business Overview, Products Offered, Recent Developments, Mnm View)*
10.1 Thermo Fisher Scientific Inc.
10.2 Catalent, Inc.
10.3 Lonza Group Ltd
10.4 Recipharm AB
10.5 Vetter Pharma International GmbH
10.6 Famar Health Care Services
10.7 Abbvie Inc.
10.8 Aenova Group
10.9 Consort Medical Plc
10.10 Almac Group
10.11 Siegfried Holding AG
10.12 Evonik Industries AG
10.13 Boehringer Ingelheim International GmbH
*Business Overview, Products Offered, Recent Developments, Mnm View Might Not Be Captured in Case of Unlisted Companies.
11 Appendix (Page No. – 179)
11.1 Insights of Industry Experts
11.2 Discussion Guide
11.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
11.4 Available Customizations
11.5 Related Reports
11.6 Author Details